Epoetin beta
NeoRecormon (epoetin beta) is a protein pharmaceutical. Epoetin beta was first approved as Neorecormon on 1997-07-16. It has been approved in Europe to treat anemia, autologous blood transfusion, chronic kidney failure, and neoplasms.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| signs and symptoms pathological conditions | D013568 |
| therapeutics | D013812 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
527 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 6 | 68 | 112 | 53 | 20 | 256 |
| Chronic renal insufficiency | D051436 | N18 | 4 | 7 | 19 | 6 | 8 | 44 | |
| Neoplasms | D009369 | C80 | — | 13 | 14 | 5 | 7 | 39 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 3 | 7 | 14 | 5 | 5 | 34 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 14 | 7 | 2 | — | 23 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
| Lymphoma | D008223 | C85.9 | 1 | 2 | 7 | 1 | 1 | 12 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
| Drug therapy | D004358 | — | 2 | 1 | 3 | — | 6 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 3 | 1 | 1 | 6 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | — | 3 | 7 | — | 1 | 11 | |
| Plasma cell neoplasms | D054219 | — | 2 | 5 | — | 1 | 8 | ||
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | — | 3 | 7 | |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
| Blood transfusion | D001803 | — | 4 | 5 | — | 1 | 7 | ||
| Orthopedic procedures | D019637 | — | 4 | 6 | — | — | 7 | ||
| Traumatic brain injuries | D000070642 | S06 | — | 3 | 4 | — | 1 | 6 | |
| Multiple myeloma | D009101 | C90.0 | — | — | 3 | — | 2 | 5 | |
| Precancerous conditions | D011230 | — | 2 | 2 | — | — | 4 | ||
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 2 | 2 | — | — | 4 |
Show 56 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 3 | — | — | 2 | 14 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
| Reperfusion injury | D015427 | 1 | 1 | — | — | 1 | 3 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | — | 2 |
| Moyamoya disease | D009072 | EFO_0004250 | I67.5 | 1 | 1 | — | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | — | — | — | 2 |
| Replacement arthroplasty knee | D019645 | — | 1 | — | — | 1 | 2 | ||
| Chronic disease | D002908 | — | 1 | — | — | 1 | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autoimmune hepatitis | D019693 | K75.4 | 1 | — | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Alveolar bone loss | D016301 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Iron metabolism disorders | D019189 | E83.1 | — | — | — | — | 1 | 1 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Uterine diseases | D014591 | N85.9 | — | — | — | — | 1 | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | — | — | — | — | 1 | 1 | |
| Hemiarthroplasty | D062785 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 | ||
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPOETIN BETA |
| INN | epoetin alfa |
| Description | Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
|
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 122312-54-3 |
| RxCUI | 105695 |
| ChEMBL ID | CHEMBL2109092 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00016 |
| UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,497 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mircera, Retacrit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
327 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more